Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARTV 
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ARTV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.4
1 Year Target Price $15.4
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.64% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.19M USD | Price to earnings Ratio - | 1Y Target Price 15.4 |
Price to earnings Ratio - | 1Y Target Price 15.4 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.47 - 17.31 | Updated Date 08/29/2025 |
52 Weeks Range 1.47 - 17.31 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.15 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.77 | Actual -0.87 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.57% | Return on Equity (TTM) -86.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -52153544 | Price to Sales(TTM) 214.51 |
Enterprise Value -52153544 | Price to Sales(TTM) 214.51 | ||
Enterprise Value to Revenue 7.54 | Enterprise Value to EBITDA - | Shares Outstanding 24363100 | Shares Floating 5381728 |
Shares Outstanding 24363100 | Shares Floating 5381728 | ||
Percent Insiders 19.88 | Percent Institutions 75.94 |
Upturn AI SWOT
Artiva Biotherapeutics, Inc. Common Stock
Company Overview
History and Background
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies to treat cancer. Founded in 2019, it aims to overcome limitations of autologous cell therapies.
Core Business Areas
- Allogeneic NK Cell Therapies: Developing off-the-shelf NK cell therapies for various cancers using its AlloNK platform. Its products address unmet needs in oncology.
Leadership and Structure
The company is led by CEO Fred Aslan. Structure involves research and development, clinical operations, and commercial strategy teams.
Top Products and Market Share
Key Offerings
- AB-101: An off-the-shelf, cryopreserved, allogeneic NK cell therapy being evaluated in clinical trials for relapsed or refractory B-cell lymphomas. Competitors include autologous CAR-T therapies from companies like Novartis and Gilead, and other allogeneic cell therapy developers.
- AB-201: An ADCC-enhanced NK cell therapy targeting HER2+ solid tumors, in preclinical development. Competitors include Genentech/Roche (Herceptin, Perjeta) and other HER2-targeting therapies.
Market Dynamics
Industry Overview
The cell therapy market is experiencing rapid growth, driven by advances in immunotherapy and gene editing. Oncology remains a primary focus.
Positioning
Artiva is positioned as an innovator in the allogeneic NK cell therapy space, aiming to provide accessible and scalable cell therapies. Competitive advantages include its AlloNK platform and partnerships.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is estimated to reach tens of billions of dollars. Artiva is targeting specific cancer indications within this larger TAM, seeking to capture a significant share with its differentiated approach.
Upturn SWOT Analysis
Strengths
- AlloNK platform for scalable NK cell production
- Strong partnerships with leading institutions
- Potential for off-the-shelf cell therapies
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Reliance on clinical trial success
- Competition from established players in cell therapy
Opportunities
- Expanding pipeline to new cancer indications
- Securing regulatory approvals for lead candidates
- Partnering with pharmaceutical companies for commercialization
- Advancements in NK cell engineering
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cell therapy companies
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- NK (NantKwest)
- GILD (Gilead Sciences)
- NVS (Novartis)
Competitive Landscape
Artiva competes with companies developing cell therapies, including those targeting CAR-T and other NK cell approaches. Its competitive advantage lies in its AlloNK platform and potential for scalable manufacturing.
Growth Trajectory and Initiatives
Historical Growth: Since its founding, Artiva has focused on preclinical development and early-stage clinical trials.
Future Projections: Future growth depends on clinical trial successes and regulatory approvals. Analyst estimates vary based on clinical pipeline progress.
Recent Initiatives: Recent initiatives include advancing clinical trials for AB-101 and AB-201 and expanding collaborations with research institutions.
Summary
Artiva Biotherapeutics is a high-risk, high-reward clinical-stage company pioneering allogeneic NK cell therapies. Its strengths lie in its innovative platform and strategic partnerships. However, the company faces challenges typical of biotech firms, including clinical trial risks and financial sustainability. The company needs to achieve milestone clinical trial success to bring the company to positive valuations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q), press releases, investor presentations, industry reports, analyst reports.
Disclaimers:
This analysis is based on available public information and does not constitute financial advice. Market conditions and company performance can change rapidly. Market share data are estimates and may not reflect precise figures. Competitor data is based on current understanding of competitive landscape.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artiva Biotherapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-07-19 | President, CEO & Director Dr. Fred Aslan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.artivabio.com |
Full time employees 105 | Website https://www.artivabio.com | ||
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.